Clinical trials | Phase | N | Line | Population | Regimen |
---|---|---|---|---|---|
NCT03980925 | II | 38 | First-line | Metastatic SCLCs or poorly differentiated NECs | Nivolumab + etoposide + carboplatin |
NCT03901378 | II | / | First-line or second-line | Metastatic or unresectable recurrent LCNECs or GEP-NECs | Pembrolizumab + platinum + etoposide |
NCT05058651 | II/III | 189 | First-line | Extrapulmonary poorly differentiated, small cell NECs. | Atezolizumab + cisplatin/carboplatin + etoposide |
NCT03591731 | II | 185 | First-line or second-line | Metastatic or unresectable recurrent LCNEC or GEP-NECs | Nivolumab + ipilimumab |
NCT04079712 | II | 30 | ≥Second-line | Advanced NECs, after the failure of at least one line of prior therapy. | Nivolumab + ipilimumab + cabozantinib |
NCT04197310 | II | 35 | First-line | Locally unresectable or metastatic nonpancreatic WD-NETs | Nivolumab + cabozantinib |
NCT04400474 | II | 144 | ≥Second-line | Advanced and progressive neoplasms of the endocrine system | Cabozantinib + atezolizumab |
NCT04579757 | Ib/II | 120 | ≥Second-line | Advanced solid tumors including low/moderate thoracogenic NETs | Surufatinib+ tislelizumab |
NCT04525638 | II | 30 | First-line or second-line | Advanced/metastatic, well-differentiated grade 3 NETs or NECs of the pancreas, gastrointestinal tract, lung and unknown primary site. | Nivolumab + 177Lu-DOTATATE |
NCT02554812 (JAVELIN Medley) | Ib/II | 398 | First-line or second-line | Locally advanced or metastatic solid tumors including advanced/metastatic SCLCs | Utomilumab + avelumab |
NCT03126110 | I/II | 145 | ≥Second-line | Advanced or metastatic malignancies including NETs | INCAGN01876 + nivolumab + ipilimumab |
NCT03241173 | I/II | 52 | ≥Second-line | Advanced or metastatic malignancies including NETs | INCAGN01949 + nivolumab, ipilimumab, or both |
NCT03026166 | I/II | 42 | ≥Second-line | SCLCs | Rova-T + nivolumab or nivolumab + ipilimumab |
NCT04192682 | II | 40 | ≥Second-line | SCLCs | Anlotinib + sintilimab |
NCT03575793 | I/II | 55 | ≥Second-line | Recurrent SCLCs | Plinabulin + nivolumab + ipilimumab |
NCT03071406 | II | 50 | ≥Second-line | Metastatic MCCs | Nivolumab + ipilimumab ± SBRT |
NCT03304639 | II | 100 | First-line or second-line | Metastatic MCCs | Nivolumab + pembrolizumab or radiation therapy |
NCT04261855 | I/II | 65 | First-line | Metastatic MCCs | Avelumab + external beam radiation therapy or 177-Lu-DOTATATE |
NCT02643303 | I/II | 58 | Any number of prior systemic therapies | Metastatic MCCs | Tremelimumab + durvalumab + polyICLC |
NETs, neuroendocrine tumors. NECs, neuroendocrine carcinomas. NENs, neuroendocrine neoplasms. WD, well differentiated. GEP, gastro-entero-pancreatic. SCLCs, small cell lung cancers. MCC, Merkel cell carcinoma. LCNEC, large cell neuroendocrine carcinoma. N, number of patients expected or actually enrolled.